SAN DIEGO, May 28, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it has been awarded Chinese Patent No.
ZL201080019566.9 entitled, DEVICES AND METHODS OF CELL CAPTURE AND
ANALYSIS. The issued patent covers methods and devices for the
capture of rare cells of interest, including CTCs that are shed
into the blood stream by solid tumors where an antibody, or mixture
of antibodies, and a microchannel are used for cell capture,
detection, and analysis. The patent encompasses the use of any
biological sample type of interest and is the 33rd
patent issued to Biocept that is core to its liquid biopsy
technology and commercial testing platforms.
"The granting of this patent further expands Biocept's
international footprint for capturing and analyzing rare cells from
biological fluids, such as blood, bone marrow, cerebral spinal
fluid (CSF), and tissue, to assess the status of patients with
cancer," said Lyle Arnold, Ph.D.,
Chief Scientific Officer at Biocept. "This technology interfaces
well with Biocept's other patented liquid biopsy technologies that
include a blood collect tube and circulating tumor DNA (ctDNA)
analysis, which are intended to aid physicians in the treatment of
their patients with cancer."
"Obtaining this new patent provides additional intellectual
property coverage for the unique and novel features of our Target
Selector™ platform, featuring our antibody cocktail and
microchannel capture technologies for CTCs and other rare cells of
interest," said Michael Nall,
Biocept's President and CEO. "We believe that the issuance of
additional patents around the world leverages our investment in our
cutting-edge liquid biopsy technologies and expands the opportunity
for Biocept to generate revenue in territories outside the
U.S."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to provide
physicians with clinically actionable information to improve the
outcomes of patients diagnosed with cancer, the utility of our
intellectual property protections, and our ability to expand
opportunities to generate revenues in territories outside the U.S.,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject
to numerous risk factors as set forth in our Securities and
Exchange Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
(310) 691-7100
View original
content:http://www.prnewswire.com/news-releases/biocept-awarded-patent-in-china-for-its-circulating-tumor-cell-platform-expanding-intellectual-property-estate-to-33-issued-patents-globally-300857051.html
SOURCE Biocept, Inc.